A recent survey by MasterControl highlights a significant concern within the pharmaceutical industry: while leaders are optimistic about AI's potential, they struggle with employee engagement in quality systems, which is crucial for AI implementation.
The survey, involving 300 quality and manufacturing leaders in the life sciences sector, revealed that 94% of pharmaceutical quality leaders see poor employee adoption of quality systems as a major challenge. This issue raises questions about the feasibility of integrating AI into workflows that employees are already reluctant to engage with. Despite these hurdles, 86% of leaders believe AI is meeting or exceeding expectations, indicating a general optimism about its role in enhancing operations.
Data privacy and integration challenges emerged as primary barriers to effective AI deployment, with 25% of respondents citing data security concerns and 59% identifying the need for integrated systems as critical. Notably, 43% of pharmaceutical leaders ranked quality defect prediction and prevention as a top priority for AI application, underscoring the importance of improving decision-making processes and system visibility.
However, the survey also revealed that manual processes remain prevalent in manufacturing, with 79% of leaders acknowledging inefficiencies. This highlights the gap between current practices and the potential benefits of AI. As David Edwards, CEO of MasterControl, noted, the success of AI is contingent upon overcoming integration gaps and legacy systems, emphasizing the strategic importance of a unified quality and manufacturing platform.